Last reviewed · How we verify
Zavzpret (Zavegepant Hydrochloride)
Zavzpret blocks the action of calcitonin gene-related peptide, a molecule involved in pain transmission.
Zavzpret (Zavegepant Hydrochloride) is a calcitonin gene-related peptide type 1 receptor antagonist, a small molecule developed by Pfizer, approved in 2023 for the treatment of migraine with aura and migraine without aura. It works by blocking the action of calcitonin gene-related peptide, a molecule involved in pain transmission. Zavzpret is a patented medication with no generic manufacturers available. Key safety considerations include the need for further studies to determine its long-term effects. Pfizer remains the current owner of the medication.
At a glance
| Generic name | Zavegepant Hydrochloride |
|---|---|
| Sponsor | Pfizer |
| Drug class | Calcitonin Gene-related Peptide Receptor Antagonist |
| Target | Calcitonin gene-related peptide type 1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2023 |
Mechanism of action
Zavegepant is calcitonin gene-related peptide (CGRP) receptor antagonist.
Approved indications
- Migraine with aura
- Migraine without aura
Common side effects
- Taste Disorders
- Nausea
- Nasal Discomfort
- Vomiting
Key clinical trials
- A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine (PHASE1)
- A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling (PHASE1)
- A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants (PHASE3)
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications (PHASE4)
- A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults (PHASE3)
- Acute Migraine Treatment in the ED With Gepants (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention (PHASE2,PHASE3)
- A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zavzpret CI brief — competitive landscape report
- Zavzpret updates RSS · CI watch RSS
- Pfizer portfolio CI